Видео ютуба по тегу Biovie

BioVie CEO Cuong Do on Phase 3 Strategy & Market Potential in CNS and Liver Disease
BioVie CEO Cuong Do on Phase 3 Strategy & Market Potential in CNS and Liver Disease
BioVie (NASDAQ: BIVI) продвигает исследования по лечению болезни Паркинсона и длительной COVID-19
BioVie (NASDAQ: BIVI) продвигает исследования по лечению болезни Паркинсона и длительной COVID-19
BioVie: Big Clinical Opportunities Ahead in 2025 | 30 Second Overview
BioVie: Big Clinical Opportunities Ahead in 2025 | 30 Second Overview
BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Metabolic Anti-Inflammatory Therapy
BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Metabolic Anti-Inflammatory Therapy
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BioVie's Novel Approach in the Battle Against Alzheimer's and Parkinson's
BioVie's Novel Approach in the Battle Against Alzheimer's and Parkinson's
Breakthrough Parkinson’s Trial Goes Decentralized | BioVie Inc. at ATMRD Congress
Breakthrough Parkinson’s Trial Goes Decentralized | BioVie Inc. at ATMRD Congress
Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc
Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc
BioVie Targets Parkinson’s & Long COVID - DNA Age Reversal & Inflammation Insights
BioVie Targets Parkinson’s & Long COVID - DNA Age Reversal & Inflammation Insights
BioVie Investor Webinar and Q&A | Oct 08, 2025
BioVie Investor Webinar and Q&A | Oct 08, 2025
Company Overview by Cuong Do, President and CEO of BioVie (BIVI)
Company Overview by Cuong Do, President and CEO of BioVie (BIVI)
BioVie AGM 2025 | Nov 10, 2025
BioVie AGM 2025 | Nov 10, 2025
Biovie’s Groundbreaking Drug for Long COVID & Parkinson’s | Bloomberg TV | New to The Street Ep. 659
Biovie’s Groundbreaking Drug for Long COVID & Parkinson’s | Bloomberg TV | New to The Street Ep. 659
BioVie публикует результаты второй фазы испытаний препарата для лечения болезни Паркинсона
BioVie публикует результаты второй фазы испытаний препарата для лечения болезни Паркинсона
BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026
BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026
Introduction To BioVie Inc & Its Pipeline With The CEO | NASDAQ: BIVI
Introduction To BioVie Inc & Its Pipeline With The CEO | NASDAQ: BIVI
BioVie Pharma: Potential solutions for Alzheimer's, Parkinson's
BioVie Pharma: Potential solutions for Alzheimer's, Parkinson's
A Huge Risk I See in BioVie's New Filing
A Huge Risk I See in BioVie's New Filing
Vos questions sur la plaque mucoide : Zencleanz x Biovie
Vos questions sur la plaque mucoide : Zencleanz x Biovie
BioVie Inc. Findings: Enhancing Motor Control in Parkinson's Patients
BioVie Inc. Findings: Enhancing Motor Control in Parkinson's Patients
Biovie Interview
Biovie Interview
🔴 BioVie Inc. BIVI Stock Trading Facts 🔴
🔴 BioVie Inc. BIVI Stock Trading Facts 🔴
BioVie shares new insight behind NE3107 molecule development and inhibiting inflammation
BioVie shares new insight behind NE3107 molecule development and inhibiting inflammation
BioVie (NASDAQ: BIVI): New solutions for Alzheimer's, Parkinson's
BioVie (NASDAQ: BIVI): New solutions for Alzheimer's, Parkinson's